Skip to main content

Biotechnology Value Fund L P's Form 4 filing

Eledon Pharmaceuticals, Inc. (ELDN) · filed May 9, 2023

Accession no.
0000921895-23-001098
Filed
May 9, 2023, 8:25 PM ET
Trade date
May 5, 2023
Filing delay
4 days
Rule 10b5-1 plan
Not checked

This filing lists 3 non-derivative transactions and 6 derivative transactions. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Biotechnology Value Fund L PCIK 0000918923Other: See Explanation of Responses
BVF Partners L PCIK 000105594710% Owner
BVF IncCIK 000105680710% Owner
Biotechnology Value Fund II LPCIK 0001102444Other: See Explanation of Responses
Lampert Mark NCIK 000123384010% Owner
Biotechnology Value Trading Fund OS LPCIK 0001660683Other: See Explanation of Responses
BVF Partners OS Ltd.CIK 0001660684Other: See Explanation of Responses
BVF I GP LLCCIK 0001803805Other: See Explanation of Responses
BVF II GP LLCCIK 0001803806Other: See Explanation of Responses
BVF GP Holdings LLCCIK 000180380910% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
May 5, 2023Common Stock, $0.001 par valuePPurchaseAcquired+1,055,445––2,330,418Direct
May 5, 2023Common Stock, $0.001 par valuePPurchaseAcquired+837,146––1,812,558Direct
May 5, 2023Common Stock, $0.001 par valuePPurchaseAcquired+86,341––145,029Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
May 5, 2023Common Stock, $0.001 par valuePPurchaseAcquired+2,028,645––2,028,645Direct
May 5, 2023Common Stock, $0.001 par valuePPurchaseAcquired+1,609,063––1,609,063Direct
May 5, 2023Common Stock, $0.001 par valuePPurchaseAcquired+165,950––165,950Direct
May 5, 2023Common Stock, $0.001 par valuePPurchaseAcquired+3,084,090––3,084,090Direct
May 5, 2023Common Stock, $0.001 par valuePPurchaseAcquired+2,446,209––2,446,209Direct
May 5, 2023Common Stock, $0.001 par valuePPurchaseAcquired+252,291––252,291Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)